How to buy Abiomed shares

Own Abiomed shares in just a few minutes.

Fact checked

Abiomed, Inc (ABMD) is a leading medical devices business based in the US. Abiomed is listed on the NASDAQ and employs 1,536 staff. All prices are listed in US Dollars.

How to buy shares in Abiomed

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ABMD in this case.
  5. Research Abiomed shares. The platform should provide the latest information available.
  6. Buy your Abiomed shares. It's that simple.

How has Coronavirus impacted Abiomed's share price?

Since the stock market crash in March caused by coronavirus, Abiomed's share price has had significant positive movement.

Its last market close was $265.86, which is 37.28% up on its pre-crash value of $166.74 and 123.39% up on the lowest point reached during the March crash when the shares fell as low as $119.0101.

If you had bought $1,000 worth of Abiomed shares at the start of February 2020, those shares would have been worth $711.99 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,430.33.

Abiomed share price

Use our graph to track the performance of ABMD stocks over time.

Abiomed shares at a glance

Information last updated 2020-09-21.
52-week range$130.01 - $319.19
50-day moving average $297.5427
200-day moving average $229.8621
Wall St. target price$326.4
PE ratio 79.3506
Dividend yield N/A (0%)
Earnings per share (TTM) $3.473
Promoted
eToro Free Stocks

Invest in Abiomed shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Your first 50 trades are free with Fineco, until 30/09/2020. T&Cs apply. Capital at risk.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.

Is it a good time to buy Abiomed stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Abiomed under- or over-valued?

Valuing Abiomed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abiomed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abiomed's P/E ratio

Abiomed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 79x. In other words, Abiomed shares trade at around 79x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Abiomed's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.

Abiomed's PEG ratio

Abiomed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abiomed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Abiomed's PEG ratio in relation to those of similar companies.

Abiomed's EBITDA

Abiomed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $244.9 million (£0.0 million).

The EBITDA is a measure of a Abiomed's overall financial performance and is widely used to measure a its profitability.

To put Abiomed's EBITDA into context you can compare it against that of similar companies.

Abiomed financials

Revenue TTM $798.1 million
Operating margin TTM 27.98%
Gross profit TTM $689.6 million
Return on assets TTM 11.76%
Return on equity TTM 15.08%
Profit margin 19.88%
Book value $24.461
Market capitalisation $12.4 billion

TTM: trailing 12 months

How to short and sell Abiomed shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ABMD.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 2.2 million Abiomed shares held short by investors – that's known as Abiomed's "short interest". This figure is 1.2% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting Abiomed shares can be evaluated.

Abiomed's "short interest ratio" (SIR)

Abiomed's "short interest ratio" (SIR) is the quantity of Abiomed shares currently shorted divided by the average quantity of Abiomed shares traded daily (recently around 298375.03467406). Abiomed's SIR currently stands at 7.21. In other words for every 100,000 Abiomed shares traded daily on the market, roughly 7210 shares are currently held short.

To gain some more context, you can compare Abiomed's short interest ratio against those of similar companies.

However Abiomed's short interest can also be evaluated against the total number of Abiomed shares, or, against the total number of tradable Abiomed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abiomed's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Abiomed shares in existence, roughly 50 shares are currently held short) or 0.0548% of the tradable shares (for every 100,000 tradable Abiomed shares, roughly 55 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Abiomed.

Find out more about how you can short Abiomed stock.

Abiomed share dividends

We're not expecting Abiomed to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

You may also wish to consider:

Have Abiomed's shares ever split?

Abiomed's shares were split on a 2:1 basis on 2 October 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Abiomed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Abiomed shares which in turn could have impacted Abiomed's share price.

Abiomed share price volatility

Over the last 12 months, Abiomed's shares have ranged in value from as little as $130.01 up to $319.19. A popular way to gauge a stock's volatility is its "beta".

ABMD.US volatility(beta: 1.14)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abiomed's is 1.1427. This would suggest that Abiomed's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Abiomed's beta into context you can compare it against those of similar companies.

Abiomed overview

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site